jeudi 13 septembre 2018

Onco Actu du 13 septembre 2018

1. Biologie

Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows [NCI]

1.4 Biologie - Technos

New Technique Limits CRISPR-Cas9 Off-Target Mutations [The Scientist]

2. Etiologie

Pilot study identifies strain of bacteria as chief risk factor for stomach cancer [Fred Hutch]

After valsartan recall, study offers 'modest reassurance' on short-term cancer risk [CNN]

2.6 Etiologie - Environnement

Despite continued public debate, weed killer glyphosate is safe, EPA says [Genetic Literacy Project]

3.1.1 Prévention - Tabac - e-cigs

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to address epidemic of youth e-cigarette use [FDA]

If It Wanted To, The FDA Could Destroy E-Cigarette Makers [Forbes]

FDA Launches Crackdown on Juul, Other E-Cigarettes [Wired]

FDA proposed crackdown on flavored e-cigs puts Juul on notice [Reuters]

4. Dépistage, diagnostic et pronostic

Problematic PR releases: Costs are hidden in cancer testing news [HealthNewsReview]

4.11 Dép., diag. & prono. - Ovaire

Simple urine test for ovarian cancer which could radically improve survival rates on the horizon [The Telegraph]

4.2 Dép., diag. & prono. - Génome

Study cracks open the secrets of the cancer-causing BRCA1 gene [STAT]

Huge genetic-screening effort helps pinpoint roots of breast cancer [Nature]

5.10 Traitements - Essais

Universities are worse than drug companies at reporting clinical trial results [Science]

Half of Europe's clinical trials fail to report results despite EU rule [Reuters]

5.12 Immunothérapies

Predicting response to immunotherapy [NIH]

5.12.5 Immunothérapies - Pharma

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%) [Merck]

5.2.3 Pharma - économie

Atreca bags $125M as solid tumor trial comes into view [FierceBiotech]

Atreca banks a $125M mega-round as it builds a pipeline of antibodies for cancer and ponders IPO timing [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

More and More, New Drugs Clear the FDA With ‘Accelerated Approval’ [Undark]

5.4 Traitements - Economie

The Curious Case Of Gleevec Pricing [Forbes]

5.9 AACR

AACR Releases Annual Cancer Progress Report [AACR]

6. Lutte contre les cancers

To The Last Drop [Journal of Clinical Oncology]

6.1 Observation

Cancer will kill 9.6m people this year, experts predict [The Guardian]

Cancer deaths rise to 9.6 million as populations grow and age [Reuters]

Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 [IARC]

6.10 Politiques

Sixteen EU Member States Sign the Genomics Declaration [ESMO]

6.5 Médecines alternatives/complémentaires

Is cancer fundraising fuelling quackery? [BMJ]

6.6 Publications

Scientific publishing: How much is too much? [Stanford Medicine]

Scientific publishing is a rip-off. We fund the research – it should be free [The Guardian]

Some scientists publish more than 70 papers a year. Here’s how—and why—they do it [Science]

Thousands of scientists publish a paper every five days [Nature]

6.7 DMP, Big Data & applis

With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care [Xconomy]